Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1042/CS20200901 http://scihub22266oqcxt.onion/10.1042/CS20200901 33063823!9055624!33063823     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33063823&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Clin+Sci+(Lond) 2020 ; 134 (19): 2645-2664 Nephropedia Template TP {{tp|p=33063823|t=2020. Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease |pdf=|usr=}}{{33063823}} gab.com Text Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease JO: Clin Sci (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=33063823 #FOAvip The virulence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the aggressive nature of the disease has transformed the universal pace of research in the desperate attempt to seek effective therapies to halt the morbidity and mortality of this pandemic. The rapid sequencing of the SARS-CoV-2 virus facilitated identification of the receptor for angiotensin converting enzyme 2 (ACE2) as the high affinity binding site that allows virus endocytosis. Parallel evidence that coronavirus disease 2019 (COVID-19) disease evolution shows greater lethality in patients with antecedent cardiovascular disease, diabetes, or even obesity questioned the potential unfavorable contribution of angiotensin converting enzyme (ACE) inhibitors or angiotensin II (Ang II) receptor blockers as facilitators of adverse outcomes due to the ability of these therapies to augment the transcription of Ace2 with consequent increase in protein formation and enzymatic activity. We review, here, the specific studies that support a role of these agents in altering the expression and activity of ACE2 and underscore that the robustness of the experimental data is associated with weak clinical long-term studies of the existence of a similar regulation of tissue or plasma ACE2 in human subjects. Twit Text FOAVip Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease ????Clin Sci (Lond) http://www.kidney.de/pget.php?&tw=1&pmid=33063823 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33063823 #FOAvip English Wikipedia <ref>{{Cite pmid|33063823}}</ref> Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease #MMPMID33063823 Ferrario CM; Ahmad S; Groban L Clin Sci (Lond) 2020[Oct]; 134 (19): 2645-2664 PMID33063823show ga The virulence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the aggressive nature of the disease has transformed the universal pace of research in the desperate attempt to seek effective therapies to halt the morbidity and mortality of this pandemic. The rapid sequencing of the SARS-CoV-2 virus facilitated identification of the receptor for angiotensin converting enzyme 2 (ACE2) as the high affinity binding site that allows virus endocytosis. Parallel evidence that coronavirus disease 2019 (COVID-19) disease evolution shows greater lethality in patients with antecedent cardiovascular disease, diabetes, or even obesity questioned the potential unfavorable contribution of angiotensin converting enzyme (ACE) inhibitors or angiotensin II (Ang II) receptor blockers as facilitators of adverse outcomes due to the ability of these therapies to augment the transcription of Ace2 with consequent increase in protein formation and enzymatic activity. We review, here, the specific studies that support a role of these agents in altering the expression and activity of ACE2 and underscore that the robustness of the experimental data is associated with weak clinical long-term studies of the existence of a similar regulation of tissue or plasma ACE2 in human subjects. |Angiotensin-Converting Enzyme 2[MESH] |Angiotensin-Converting Enzyme Inhibitors/pharmacology[MESH] |Betacoronavirus/*pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/drug therapy/enzymology/*virology[MESH] |Humans[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/*drug effects/metabolism[MESH] |Pneumonia, Viral/drug therapy/enzymology/*virology[MESH] |SARS-CoV-2[MESH]Twenty years of progress in angiotensin converting enzyme 2 and its li(epmc).pdf DeepDyve Pubget Overpricing